In order to create effective vaccines and therapeutics against a virus, it is necessary to have an intricate understanding of its biology as well as its method of immunological evasion. We offer a comprehensive portfolio of services for vaccine and therapy development that targets HPV infection.
Human Papillomavirus, (hpv) refers to a group of more than 200 related viruses, over 40 of which are sexually active and are passed through direct skin movement. HPV can be further classified into two general types; low risks and high risks type. The low risks type can cause conditions such as genital warts which are benign, while the high risks type are linked with the development of different types of cancer including cervical anal and oropharyngeal cancers. High risk HPV type infections that are associated with HPV 16 and 18 alone may contribute up to 80% of cervical cancer cases worldwide which translate to over 570,000 new cases and 300,000 deaths annually.
Fig.1 Progression of human papillomavirus infection and associated disease. (Shanmugasundaram S., et al., 2017)
Table 1 Adverse effects of bivalent and quadrivalent HPV vaccines. (Kamolratanakul S., et al., 2021)
| Adverse Effect | Vaccine Type | Relative Risk | 95% CI |
|---|---|---|---|
| Overall adverse effects at the injection site | Bivalent and quadrivalent | 1.18 | 1.16 to 1.20 |
| Overall systemic events | Bivalent and quadrivalent | 1.02 | 0.98 to 1.07 |
| Serious adverse event | Bivalent and quadrivalent | 1.01 | 0.95 to 1.07 |
| Autoimmune-related conditions | Bivalent | 0.98 | 0.80 to 1.21 |
| Thromboembolic event | Quadrivalent | 0.7 | 0.3 to 1.4 |
| Chronic fatigue syndrome | Quadrivalent | 0.94 | 0.78 to 1.14 |
| Multiple sclerosis | Quadrivalent | 0.3 | 0.1 to 0.9 |
| Connective disorders | Quadrivalent | 0.8 | 0.3 to 2.4 |
| Type 1 diabetes | Quadrivalent | 1.2 | 0.4 to 3.6 |
| Guillain–Barré syndrome (GBS) | Bivalent and quadrivalent | 3.78 | 1.79 to 7.98 |
| Bivalent | 8.08 | 1.69 to 38.61 | |
| Quadrivalent | 3.78 | 1.70 to 8.41 | |
| Thyroiditis | Bivalent | 3.75 | 1.25 to 11.31 |
| Inflammatory bowel disease | Bivalent and quadrivalent | 1.14 | 0.97 to 1.35 |
| Bivalent | 1.11 | 0.75 to 1.66 |
E2 Protein Modulators
Compounds designed specifically for inhibiting the e2 protein which facilitate nucleic acid handling and transcription are currently under analysis. In a similar manner, if cell's oncogenes are lost, Agents could add the protection by stopping cells from turning malignant.
Checkpoint Inhibitors
Immunization agents are immunobiological drugs designed to enhance an individual's immunity against HPV, which includes pembrolizumab, an immune checkpoint inhibitor that facilitates T-cell responses to dester infections caused by HPV. These drugs are now being evaluated for their usfulness against HPV related cancers.
We adopt cutting-edge technologies to formulate the most appropriate prophylactic and therapeutic vaccines for targeted HPV types. We aim to identify novel targets for new drug development with respect to therapeutics. We use a multidisciplinary approach and apply methodologies in molecular biology, virology, and immunology to develop personal vulgar solutions to persistent HPV infection.
In addition, our team focuses on identifying biomarkers that predict response to HPV therapies, enabling the development of personalized therapeutic approaches. If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
